

AGIOS PHARMACEUTICALS INC

Form 8-K

December 08, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 7, 2014

Agios Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction

of Incorporation)

001-36014
(Commission

File Number)

26-0662915
(IRS Employer

Identification No.)

38 Sidney Street, 2nd Floor, Cambridge, MA

02139

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (617) 649-8600

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On December 7, 2014, Agios Pharmaceuticals, Inc. (the Company) issued a press release announcing new phase 1 data on AG-221, its first-in-class inhibitor of IDH2 mutations in patients with advanced hematologic malignancies, including acute myeloid leukemia. On December 8, 2014, the Company issued a press release announcing first clinical data from its Phase 1 single (SAD) and multiple ascending dose (MAD) clinical trials of AG-348, its first-in-class oral activator of pyruvate kinase-R for the treatment of pyruvate kinase deficiency, a cause of hemolytic anemia, in healthy volunteers. The Company presented both data at the 2014 American Society of Hematology Annual Meeting and Exposition held on December 6 - 9, 2014. The full text of the press releases issued in connection with this announcement is attached as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

| No. | Description |
|------|--------------------------------------------------------------------------|
| 99.1 | Press release issued by Agios Pharmaceuticals, Inc. on December 7, 2014. |
| 99.2 | Press release issued by Agios Pharmaceuticals, Inc. on December 8, 2014. |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AGIOS PHARMACEUTICALS, INC.

Date: December 8, 2014

By: /s/ David P. Schenkein, M.D.
David P. Schenkein, M.D.

Chief Executive Officer

EXHIBIT INDEX

| Exhibit No. | Description |
|----------------|--------------------------------------------------------------------------|
| 99.1 | Press release issued by Agios Pharmaceuticals, Inc. on December 7, 2014. |
| 99.2 | Press release issued by Agios Pharmaceuticals, Inc. on December 8, 2014. |